ImmuCell Corporation (ICCC)vsBeiGene, Ltd. (ONC)
ICCC
ImmuCell Corporation
$10.13
+1.81%
HEALTHCARE · Cap: $87.01M
ONC
BeiGene, Ltd.
$365.67
+4.23%
HEALTHCARE · Cap: $39.69B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 19880% more annual revenue ($6.13B vs $30.68M). ONC leads profitability with a 10.7% profit margin vs 2.6%. ONC trades at a lower P/E of 62.9x. ONC earns a higher WallStSmart Score of 64/100 (C+).
ICCC
Hold47
out of 100
Grade: D+
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.5%
Fair Value
$17.78
Current Price
$10.13
$7.65 discount
Margin of Safety
+80.0%
Fair Value
$1758.06
Current Price
$365.67
$1392.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 259.9% YoY
Reasonable price relative to book value
Strong operational efficiency at 26.9%
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
2.6% margin — thin
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCC
The strongest argument for ICCC centers on EPS Growth, Price/Book, Operating Margin. Revenue growth of 11.5% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Profit Margin. A P/E of 136.9x leaves little room for execution misses. Thin 2.6% margins leave little buffer for downturns.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 62.9x leaves little room for execution misses.
Key Dynamics to Monitor
ICCC profiles as a value stock while ONC is a growth play — different risk/reward profiles.
ICCC carries more volatility with a beta of 0.55 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 47/100) and 29.6% revenue growth. ICCC offers better value entry with a 63.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?